Science & Technology 
Science and Technology
Science and Technology 
Tue, February 3, 2009
Aethlon Medical Provides Clinical Update at International Conference on Dialysis
SAN DIEGO--([ BUSINESS WIRE ])--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that its Chief Science Officer, Dr. Richard H. Tullis presented a clinical report on the Aethlon Hemopurifier® to Nephrologists attending the International Conference on Dialysis on January 29th. The focal point of Dr. Tullis's presentation was the use of the Hemopurifier® to manage disease progression in end-stage renal disease (ESRD) patients infected with viral pathogens, including Hepatitis-C (HCV) and Human Immunodeficiency Virus (HIV). Aethlon anticipates Nephrologists will become early adopters of the Hemopurifier® as viral infection significantly increases patient mortality in ESRD patients who require regular dialysis treatment.
Aethlon Chairman and CEO, Jim Joyce stated, "Rick's presentation was very well received and triggered further inquiries from medical organizations interested in advancing clinical programs with us in the United States."
Aethlon also disclosed that it now has over sixty (60) treatment experiences in twelve dialysis patients, which represents approximately 240 hours of Hemopurifier® treatment in ESRD patients. In each of these treatments, the Hemopurifier® was administered in series with the patient's dialysis cartridge without diminishing the effectiveness of dialysis treatment. As a result, the additional benefit of the Hemopurifier® was provided without modification to the patient's treatment schedule and without the need for additional staffing requirements.
Aethlon additionally announced that it is nearing completion of a 30-day HCV treatment case study, and that it expects to have data resulting from a recently completed 30-day HIV treatment case study in the coming weeks. The clinical insight obtained from each case study will assist Aethlon in designing future clinical programs and commercialization strategies.
Aethlon recently reported robust viral load reductions in three HCV-infected ESRD patients that completed a three Hemopurifer(R) treatment protocol at the Fortis Hospital in Delhi, India. Patient #1 had a 95% reduction three days post treatment and 89% reduction seven days post treatment. The initial viral load for patient 1 was 5.3 x 10(5) viral units per ml of blood (IU/ml). Patient 1's viral load seven days post treatment was 5.7 x 10(4) IU/ml.
Patient #2 had a 85% reduction three days post treatment and 50% reduction seven days post treatment. The initial viral load for patient 2 was 9.2 x 10(6) IU/ml. Patient 2's viral load seven days post treatment was 4.6 x 10(6) IU/ml.
Patient #3 had a 60% reduction three days post treatment and 83% reduction seven days post treatment. The initial viral load for patient 3 was 3.0 x 10(8) IU/ml. Patient 3's viral load seven days post treatment was 5.1 x 10(7) IU/ml. All viral load measurements were performed with real-time quantitative polymerase chain reaction (RT-PCR). Control samples were measured in duplicate while treatment samples were generally measured in triplicate.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device designed to treat infectious disease. The Hemopurifier® provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier® is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier® is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier® in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier® as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States have been focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has demonstrated safety of the Hemopurifier® in a 24-treatment human study at the Apollo Hospital in Delhi, India, and in an 18-treatment study at the Fortis Hospital, also located in Delhi. The company has also submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier® as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier® technology is available online at [ www.aethlonmedical.com ].
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.